This study represents the first step on a development path that aims at improving cure rates for advanced hematologic malignancies including ALL, AML and CML-BP by simultaneously targeting different components of the PI3K/Akt/mTOR signaling pathway. This evidence concerns the gene AKT1 and chronic myelogenous leukemia, BCR-ABL1 positive.